depth of response and mrd status in ultra high-risk mm: results of the uk optimum/muknine trial
Published 3 years ago • 748 plays • Length 15:27Download video MP4
Download video MP3
Similar videos
-
1:59
optimum/muk nine clinical trial with dr martin kaiser
-
12:26
treating ultra high risk myeloma patients in a unique uk study | martin kaiser, md | ash 2021
-
5:54
results of the phase 2 ifm 2018-04 study in high-risk, transplant-eligible ndmm patients
-
7:31
multiomics profiling of mrd for understanding the biology of ultra-drug resistance in myeloma
-
5:46
mrd to assess depth of response in a high-risk myeloma patient
-
1:33:39
the relevance of mrd assessment in the clinical management of multiple myeloma (mm) patients
-
2:37
evidence supporting mrd-guided treatment breaks in mm
-
3:23
mrd-directed trials & achieving mrd negativity in patients with high-risk multiple myeloma
-
4:10
how does minimal residual disease (mrd) testing affect treatment decisions?
-
4:01
if a myeloma patient has mrd-negative status, does that mean that patient is cured?
-
59:27
imwg conference series: reporting from ash 2022
-
5:22
analysis of treatment efficacy in the gem-cesar trial for high-risk smoldering multiple myeloma pts
-
12:09
mrd2stop: can multimodal mrd negativity guide discontinuation of maintenance treatment in myeloma?
-
4:37
the role of the uk in multiple myeloma clinical trials
-
2:11
mrd as a predictor of risk in myeloma
-
35:56
international myeloma workshop 2021 | daily update, part 1 | newly diagnosed mrd
-
1:59
mrd negativity as predictors of early relapse in transplant-eligible multiple myeloma patients
-
4:44
minimal residual disease (mrd) | high impact topic (hit)
-
2:20
genomic profiling of smoldering myeloma identifies high- and low- risk patients